SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : AMLN (DIABETES DRUGS)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: D.Right who wrote (1070)2/12/1998 5:25:00 PM
From: arnie h  Read Replies (1) of 2173
 
Dear D.- Back on the matter of 75% continuing on pramlintide post trial. Based on the results released, there were 2 groups of type 2 patients who entered the study with poor glucose control but maintained stable insulin dosing; one had dosage of 75 mcg and the other 150 mcg. Reductions in HbAlc were impressive in both but were not statistically significant because of the very small size of the groups (23 and 20). If 75 % of these folks stayed with pramlintide, it would be most encouraging. Is there a way of learning whether this is so? I don't know of any reason this information should be confidential and may well be available.

Would appreciate your (or others) thoughts on how to get this info and it's possible significance.

Thank you,
Arnie
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News